Merck & Co shares jump as Keytruda grabs more ASCO headlines

3 June 2019

Merck & Co’s (NYSE: MRK) industry-leading immuno-oncology drug Keytruda (pembrolizumab) is no stranger to making the headlines at ASCO, and this year’s meeting is no exception.

Among the data that the US pharma giant has presented on its anti-PD-1 therapy at the event this time around is five-year efficacy and safety data of the drug’s use as a monotherapy in patients with advanced non-small cell lung cancer (NSCLC) from the first KEYNOTE trial.

In the Phase Ib study, Keytruda demonstrated a five-year overall survival (OS) rate of 23.2% in treatment-naïve patients and 15.5% in previously treated patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK